GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evolutionary Genomics Inc (OTCPK:FNAM) » Definitions » Cyclically Adjusted PB Ratio

Evolutionary Genomics (Evolutionary Genomics) Cyclically Adjusted PB Ratio : (As of Jun. 21, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Evolutionary Genomics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Evolutionary Genomics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Evolutionary Genomics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolutionary Genomics Cyclically Adjusted PB Ratio Chart

Evolutionary Genomics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Evolutionary Genomics Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Evolutionary Genomics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Evolutionary Genomics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evolutionary Genomics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evolutionary Genomics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Evolutionary Genomics's Cyclically Adjusted PB Ratio falls into.



Evolutionary Genomics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Evolutionary Genomics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2022 is calculated as:

For example, Evolutionary Genomics's adjusted Book Value per Share data for the three months ended in Dec. 2022 was:

Adj_Book=Book Value per Share/CPI of Dec. 2022 (Change)*Current CPI (Dec. 2022)
=-1.116/125.2218*125.2218
=-1.116

Current CPI (Dec. 2022) = 125.2218.

Evolutionary Genomics Quarterly Data

Book Value per Share CPI Adj_Book
201303 -0.501 98.209 -0.639
201306 -0.563 98.518 -0.716
201309 -0.578 98.790 -0.733
201312 -0.594 98.326 -0.756
201403 -0.602 99.695 -0.756
201406 0.008 100.560 0.010
201409 -0.062 100.428 -0.077
201412 -11.561 99.070 -14.613
201503 -0.162 99.621 -0.204
201506 -0.224 100.684 -0.279
201509 -0.316 100.392 -0.394
201512 0.496 99.792 0.622
201603 0.442 100.470 0.551
201606 -0.116 101.688 -0.143
201609 0.331 101.861 0.407
201612 0.313 101.863 0.385
201703 0.184 102.862 0.224
201706 0.133 103.349 0.161
201709 0.082 104.136 0.099
201712 0.164 104.011 0.197
201803 -0.407 105.290 -0.484
201806 0.041 106.317 0.048
201809 -0.010 106.507 -0.012
201812 -0.047 105.998 -0.056
201903 -0.089 107.251 -0.104
201906 -0.130 108.070 -0.151
201909 -0.169 108.329 -0.195
201912 -0.218 108.420 -0.252
202003 -0.262 108.902 -0.301
202006 -0.315 108.767 -0.363
202009 -0.227 109.815 -0.259
202012 -0.521 109.897 -0.594
202103 -0.611 111.754 -0.685
202106 -0.708 114.631 -0.773
202109 -0.890 115.734 -0.963
202112 -1.007 117.630 -1.072
202203 -0.894 121.301 -0.923
202206 -0.968 125.017 -0.970
202209 -1.051 125.227 -1.051
202212 -1.116 125.222 -1.116

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Evolutionary Genomics  (OTCPK:FNAM) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Evolutionary Genomics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Evolutionary Genomics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Evolutionary Genomics (Evolutionary Genomics) Business Description

Traded in Other Exchanges
N/A
Address
4220 Morning Star Drive, Castle Rock, CO, USA, 80108
Evolutionary Genomics Inc is involved in the development of a technology platform, the Adapted Traits Platform (ATP), to identify commercially valuable genes that control important traits in animals and plants. It uses the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. The company's platform identifies key genes that have changed successfully to impart new or improved traits. Its primary source of revenue had been contract services revenue for research performed by it on behalf of other commercial entities and grant income received from governmental agencies, industry associations and grant-making foundations for research performed.
Executives
Steve B Warnecke director, 10 percent owner, officer: Chairman, CEO C/O TARGETED MEDICAL PHARMA, INC., 2980 BEVERLY GLEN CIRCLE, SUITE 301, LOS ANGELES CA 90077
Virginia P. Orndorff director 4580 AUGUSTA DR., BROOMFIELD CO 80023
Walter Messier officer: Secretary / Treasurer 1586 GOSHAWK DRIVE, LONGMONT CO 80504
Mark Virgil Boggess director 7857 E OAKBROOK CIR, MADISON WI 53717
Sanford Schwartz director, 10 percent owner 5353 MANHATTAN CIRCLE, STE 101, BOULDER CO 80303
Michael Friess director, 10 percent owner, officer: President/CEO 5353 MANHATTAN CIRCLE, STE 101, BOULDER CO 80303
Chloe M Divita director, officer: Secretary/Treasurer/CFO 5353 MANHATTAN CIRCLE, SUITE 101, BOULDER CO 80303

Evolutionary Genomics (Evolutionary Genomics) Headlines

No Headlines